Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib Dose Escalation in Advanced NSCLC
NCT01465243Phase 4Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2011
- Primary completion
- Oct 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Sep 2011; status: completed.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01465243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01465243.